omeprazole has been researched along with puromycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maki, Y; Nagaya, H; Satoh, H | 1 |
| Huynh, DH; Lamé, MW; Pombo, M; Tablin, F; Walker, NJ | 1 |
2 other study(ies) available for omeprazole and puromycin
| Article | Year |
|---|---|
Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphate; Animals; Bucladesine; Carbachol; Cycloheximide; Dogs; Female; Gastric Acid; Histamine Antagonists; Lansoprazole; Male; Omeprazole; Parietal Cells, Gastric; Puromycin; Ranitidine | 1990 |
TCDD and omeprazole prime platelets through the aryl hydrocarbon receptor (AhR) non-genomic pathway.
Topics: Basic Helix-Loop-Helix Transcription Factors; Blood Platelets; Dose-Response Relationship, Drug; Enzyme Activation; Group IV Phospholipases A2; Humans; Ligands; Omeprazole; p38 Mitogen-Activated Protein Kinases; Peptide Fragments; Phosphorylation; Platelet Activation; Platelet Aggregation; Polychlorinated Dibenzodioxins; Protein Kinase Inhibitors; Proton Pump Inhibitors; Puromycin; Receptors, Aryl Hydrocarbon; Receptors, Thrombin; RNA, Messenger; Signal Transduction; Time Factors; Up-Regulation | 2015 |